Hydroxyzine

CHEMBL896 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

374.9 g/mol

LogP

3.7

Phase

4

This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.

Moleküler Ağırlık

374,9000 g/mol

LogP

3,70

TPSA

35,90 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Ovarian Cancer Pain Management Non-Small Cell Lung Cancer Asthma Migraine Schizophrenia Generalized Anxiety Disorder Oncology Multiple Sclerosis Type 2 Diabetes Major Depressive Disorder Breast Cancer Atopic Dermatitis Chronic Pain Colorectal Cancer

Etki Mekanizması

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1

InChI

InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2

Molecular Formula

C21H27ClN2O2

HBD / HBA

1 / 4

Döndürülebilir Bağlar

8

Ağır Atomlar

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Hydroxyzine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL896. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3658. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Hydroxyzine PillFYI'da

Yapı

Hızlı Veriler

Formül: C21H27ClN2O2
Eş Anlamlılar: 4

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.